KYMR vs. TEM: Kymera Therapeutics vs. Tempus AI Stock Comparison

November 11, 2026

How do Kymera Therapeutics (KYMR) and Tempus AI (TEM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Kymera Therapeutics (KYMR) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but KYMR is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Company profile comparison for Kymera Therapeutics (KYMR) and Tempus AI (TEM)
Profile Item	KYMR	TEM
Name	Kymera Therapeutics Inc.	Tempus AI Inc Class A Common Stock
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	11.25 billion USD	13.87 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	August 21, 2020	June 14, 2024
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

KYMR

TEM

GSPC

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Kymera Therapeutics (KYMR) and Tempus AI (TEM). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Kymera Therapeutics (KYMR) and Tempus AI (TEM). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Kymera Therapeutics (KYMR) and Tempus AI (TEM)
Metric	KYMR	TEM
Total Return (1Y)	131.52%	16.25%
Total Return (3Y, Annualized)	111.65%	--
Total Return (5Y, Annualized)	15.68%	--

Risk Profile

Drawdown History

KYMR

TEM

GSPC

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Kymera Therapeutics (KYMR) and Tempus AI (TEM). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Kymera Therapeutics (KYMR) and Tempus AI (TEM)
Metric	KYMR	TEM
Volatility (1Y, Annualized)	62.83%	76.08%
Beta (5Y)	2.00	3.34
Max Drawdown (5Y)	-83.27%	-59.76%
Avg. Volume (3M)	833.05K	7.20M

Risk-Adjusted Performance

Risk-Return Positioning

KYMR and TEM are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Kymera Therapeutics (KYMR) and Tempus AI (TEM)
Metric	KYMR	TEM
Sharpe Ratio (1Y)	2.03	0.16
Sortino Ratio (1Y)	4.16	0.26

Profitability

ROE (TTM)

Both Kymera Therapeutics (KYMR) at -27.29% and Tempus AI (TEM) at -37.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
KYMR: -27.29%
Q1: -64.05%
Min: -167.77%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-37.55%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
TEM: -37.55%
Q1: -64.05%
Min: -167.77%

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Kymera Therapeutics (KYMR) reports 0.00%, ranking against industry peers normally.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
KYMR: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.54%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
TEM: -12.54%
Min: -17.05%

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Kymera Therapeutics (KYMR) at -396.04% and Tempus AI (TEM) at -13.82% report negative operating margin values, usually indicating operating losses over the period.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
KYMR: -396.04%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-13.82%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
TEM: -13.82%
Q1: -78.82%
Min: -207.40%

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Kymera Therapeutics (KYMR) and Tempus AI (TEM)
Metric	KYMR	TEM
ROE (TTM)	-27.29%	-37.55%
ROA (TTM)	-17.64%	-7.36%
Net Margin (TTM)	0.00%	-12.54%
Operating Margin (TTM)	-396.04%	-13.82%
Gross Margin (TTM)	0.00%	64.46%

Growth

Revenue Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Kymera Therapeutics (KYMR) at -16.70% is in the bottom quartile, showing a clear gap in revenue momentum.

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Kymera Therapeutics (KYMR) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Kymera Therapeutics (KYMR) and Tempus AI (TEM)
Metric	KYMR	TEM
Revenue Growth (YoY)	-16.70%	83.41%
Revenue Growth (3Y CAGR)	-5.74%	58.29%
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Both Kymera Therapeutics (KYMR) at 11.13 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max: 25.13
Q3: 12.13
KYMR: 11.13
Median: 5.52
Q1: 2.47
Min: 0.10

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.61

Max: 25.13
Q3: 12.13
Median: 5.52
TEM: 2.61
Q1: 2.47
Min: 0.10

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Kymera Therapeutics (KYMR) at 0.05 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max: 1.42
Q3: 0.65
Median: 0.15
KYMR: 0.05
Q1: 0.02
Min: 0.00

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.86

TEM: 2.86
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Kymera Therapeutics (KYMR) and Tempus AI (TEM)
Metric	KYMR	TEM
Current Ratio (MRQ)	11.13	2.61
Debt / Equity (MRQ)	0.05	2.86
Net Debt / EBITDA	--	--

Dividends

Dividend Yield (TTM)

Neither Kymera Therapeutics (KYMR) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEM: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEM: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Kymera Therapeutics (KYMR) and Tempus AI (TEM)
Metric	KYMR	TEM
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
KYMR: --

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
TEM: --

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

Tempus AI (TEM) at 9.19 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR: 110.00
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.19

Max: 58.18
Q3: 25.77
TEM: 9.19
Median: 7.30
Q1: 3.01
Min: 0.01

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Kymera Therapeutics (KYMR) at 6.96 sits in the upper P/B ratio quartile, and Tempus AI (TEM) at 27.66 prices even higher, above its industry range.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max: 13.53
KYMR: 6.96
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.66

TEM: 27.66
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Kymera Therapeutics (KYMR) vs. Tempus AI (TEM): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Kymera Therapeutics (KYMR) and Tempus AI (TEM)
Metric	KYMR	TEM
P/E Ratio (TTM)	--	--
P/S Ratio (TTM)	110.00	9.19
P/B Ratio (MRQ)	6.96	27.66
Free Cash Flow Yield (TTM)	-1.46%	0.30%